vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $158.6M, roughly 1.7× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 14.9%, a 56.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 8.1%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $33.8M).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
BCPC vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $158.6M |
| Net Profit | $40.3M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 20.5% | 70.2% |
| Net Margin | 14.9% | 71.2% |
| Revenue YoY | 8.1% | 3661.1% |
| Net Profit YoY | 8.7% | 528.0% |
| EPS (diluted) | $1.25 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | — | ||
| Q3 25 | $267.6M | — | ||
| Q2 25 | $255.5M | — | ||
| Q1 25 | $250.5M | $158.6M | ||
| Q4 24 | $240.0M | $22.6M | ||
| Q3 24 | $239.9M | — | ||
| Q2 24 | $234.1M | — |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $37.1M | $112.9M | ||
| Q4 24 | $33.6M | $-10.5M | ||
| Q3 24 | $33.8M | — | ||
| Q2 24 | $32.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | — | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | 20.4% | 70.2% | ||
| Q4 24 | 19.8% | -60.4% | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 19.6% | — |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 14.8% | 71.2% | ||
| Q4 24 | 14.0% | -46.4% | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 13.7% | — |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | — | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | $1.90 | ||
| Q4 24 | $1.03 | $-0.15 | ||
| Q3 24 | $1.03 | — | ||
| Q2 24 | $0.98 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $350.1M |
| Total Assets | $1.7B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | $274.8M | ||
| Q4 24 | $49.5M | $128.0M | ||
| Q3 24 | $73.7M | — | ||
| Q2 24 | $63.7M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | $350.1M | ||
| Q4 24 | $1.1B | $229.0M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.6B | $406.9M | ||
| Q4 24 | $1.6B | $271.6M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $131.8M |
| Free Cash FlowOCF − Capex | $33.8M | $131.7M |
| FCF MarginFCF / Revenue | 12.5% | 83.0% |
| Capex IntensityCapex / Revenue | 2.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.99× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | — | ||
| Q2 25 | $47.3M | — | ||
| Q1 25 | $36.5M | $131.8M | ||
| Q4 24 | $52.3M | $-23.2M | ||
| Q3 24 | $51.3M | — | ||
| Q2 24 | $45.0M | — |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | 1.17× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
